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Abstract: Purpose of Review. This is a comprehensive review of the literature regarding the use
of Aripiprazole lauroxil for schizophrenia. This review presents the background, evidence, and
indications for using aripiprazole lauroxil to treat schizophrenia in the context of current theories
on the development of schizophrenia. Recent Findings. Schizophrenia is a chronic mental health
disorder that currently affects approximately 3.3 million people in the United States. Its symptoms,
which must be present for more than six months, are comprised of disorganized behavior and speech,
a diminished capacity to comprehend reality, hearing voices unheard by others, seeing things unseen
by others, delusions, decreased social commitment, and decreased motivation. The majority of these
symptoms can be managed with antipsychotic medication. Aripiprazole lauroxil is a long-acting
intramuscular injection that works as a combination of partial agonist activity at D2 and 5-HT1A
receptors combined with antagonist activity at 5-HT2A receptors. It can be dosed as a 4-, 6-, or
8-week injection, depending on oral dosage. Aripiprazole lauroxil was FDA approved in October of
2015. Summary. Schizophrenia is a severe psychiatric disorder if left untreated. There are multiple
medications to help treat schizophrenia. One antipsychotic agent, aripiprazole lauroxil, offers long
duration injections that optimize and improve compliance. Known side effects include weight
gain, akathisia, neuroleptic malignant syndrome, tardive dyskinesia, and orthostatic hypotension.
Aripiprazole lauroxil is an FDA-approved drug that can be administered monthly, every six weeks,
or every two months and has been shown to be both safe and effective.
Keywords: schizophrenia; schizophrenia treatment; aripiprazole lauroxil; long-acting injections;
aristada
1. Introduction
Schizophrenia is a psychotic disorder that can be characterized as having positive
symptoms, negative symptoms, and cognitive dysfunction. Positive symptoms consist
of the presence of behaviors or thoughts that are not typically present, such as psychosis,
delusions, hallucinations, disorganized speech, and behavior [1]. Negative symptoms are
characterized by social withdrawal, flat affect, anhedonia, and low energy [1]. The positive
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and negative symptoms of schizophrenia are thought to be a result of dopaminergic
dysregulation. Cognitive impairment is also a main component in schizophrenia and
is largely refractory to treatment [2]. Cognitive deficits include impairment in attention,
working memory, episodic memory, processing speed, and executive function [3]. A decline
in social and cognitive functions generally presents itself > 10 years before the onset of
psychotic symptoms and leads to those with schizophrenia encountering problems with their
ability to maintain social relationships, employment, and independence [3,4]. Although
treatment with antipsychotics and psychosocial interventions can help increase quality
of life, the severity of negative symptoms and cognitive impairment at onset can be a
determining factor in treatment efficacy [5]. The Diagnostic and Statistical Manual of
Mental Disorders 5th edition requires that psychotic symptoms be present for over six
months [6]. The lifetime prevalence of major depression in schizophrenia was found to be
between 30–50% [7,8]. 34% of patients were found to have a lifetime diagnosis of alcohol
abuse or dependence [9].
The treatment of schizophrenia is a combination of antipsychotic medications and
nonpharmacological treatment [10]. The combination of pharmacological and nonphar-
macological interventions can result in improvement in psychiatric symptoms, social
functioning, quality of life, and treatment retention, as well as reducing the need for
hospitalizations and crisis services, legal system involvement, self-harm, and substance
abuse [10]. First-generation antipsychotics (FGAs) such as haloperidol have been proven
to be effective; however, adverse effects such as Parkinsonism and tardive dyskinesia are
a hindrance to long-term use [10]. Second-generation antipsychotics (SGAs) are thought
to have equal or better efficacy than first-generation antipsychotics. SGAs are also more
useful in the treatment of negative symptoms; however, SGAs can have harmful adverse ef-
fects on the cardiovascular (QT prolongation) and endocrine systems (hyperprolactinemia,
which can cause sexual dysfunction, amenorrhea, galactorrhea and bone demineraliza-
tion) [10]. An important aspect of treating a patient with schizophrenia is “patient-level
characteristics” that can impact the outcomes of interventions [10].
2. Epidemiology
A meta-analysis found that the median estimate of the core incidence of schizophrenia
is 15.2 per 100,000 [11]. The incidence rate ratio between males and females was found to
be 1.4 [11]. The incidence ratio of schizophrenia varied significantly between migrants and
native-born individuals, with the ratio being 4.6 migrant-to-native-born [11]. The incidence
of urban and mixed urban-rural was found to be 19 and 13.3 per 100,000, respectively [11].
The median lifetime prevalence was 4.0 per 1000, and the lifetime morbid risk was 7.2 per
1000 [11].
3. Pathophysiology
It is hypothesized that schizophrenia occurs in individuals with a genetic predisposi-
tion to the disease, with environmental factors that over time lead to the progression of
schizophrenia [12]. Adoption studies of individuals adopted within three days of birth
show that the incidence of schizophrenia is the same in both the adopted subjects and those
who stay with their biological family [13]. This suggests that environmental triggers in
those with a genetic predisposition to schizophrenia occur sometime between conception
and birth in the form of epigenetic changes are thought to be one of the main reasons for
alter gene expression [14].
Serotonin plays an important role in cortical development and regulation in cognition,
mood, and impulse control; as a result, it is hypothesized that abnormal serotonergic
activity can contribute to the pathophysiology of schizophrenia [15,16]. Studies have shown
that a reduction in the serotonin 2A receptor (HTR2A), as well as HTR7, is implicated in
the pathogenesis of schizophrenia [17,18]. Neuroimaging data also suggest that levels of
HTR2A may vary at different stages of the disorder [19]. Regulating the levels of HTR2A
may also provide a new opportunity for treatment options [20].
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Acetylcholine controls the cholinergic system in the central nervous system (CNS) and
plays an important role in both learning and memory [21]. There are five different types
of muscarinic receptors, all of which are differentially expressed throughout the CNS [22].
The variable roles of each type of muscarinic receptor and their respective distribution can
help shed light on the pathophysiology of schizophrenia [20]. Low levels of the M1 receptor
(CHRM1), in particular, have been implicated in the pathogenesis of schizophrenia [23,24].
The emergence of microarray technology has allowed researchers to track gene expression
changes, including presynaptic functioning, G protein signaling, and myelination, all of
which can have implications in both diagnosing and treating schizophrenia [20,25,26].
4. Risk Factors
The development of schizophrenia has been largely based on the neurodevelopmental
theory [27]. The neurodevelopmental theory is based on a “single-hit” theory [28,29]. In
the neurodevelopment theory, it is hypothesized that brain dysconnectivity is derived
from deficits in dendritic spines during development arising from a combination of genetic
factors and obstetric complications [30,31]. These deficits may progress further, leading
to the expression of psychotic symptoms as a result of neuromaturation events such as
aggressive synaptic pruning, or elevated cortisol leading to dendritic atrophy [28,32–35].
At present, it is thought that the pathogenesis of schizophrenia is not related to a
“single hit,” rather it is the combination of “vulnerability factors” that alone have a weak
individual effect but act together at critical points of neurodevelopment, which ultimately
leads to schizophrenia [27]. These “vulnerability factors” include cannabis use, childhood
trauma, and social defeat, among others [27]. Longitudinal studies suggest that there is
up to a 40% greater risk of psychosis among people who have used cannabis [36,37]. It
is thought that adolescents who use cannabis experience the onset of their first psychotic
episode 2.7 years earlier than those with no history of cannabis use [38]. Childhood trauma
including physical abuse, emotional abuse, sexual abuse, parental loss or divorce, parental
substance abuse, poverty, and social defeat are thought to be vulnerability factors for
the later development of schizophrenia [39]. Meta-analyses suggest that those with a
history of childhood trauma have a risk of developing schizophrenia that is three times
as high as those with no history of such trauma [40]. A history of childhood trauma also
appears to be associated with worse positive symptoms as well as non-remission of positive
symptoms [41]. Social defeat is defined as “losing a confrontation amongst any type of
hostile dispute amongst humans” and consists of the stressors faced while being a part of a
marginalized or excluded social or ethnic group [27]. Some studies suggest that the risk of
schizophrenia is highest amongst immigrant groups who experience low social integration,
poverty, alienation, and social uprooting [42].
5. Presentation
Schizophrenia presents a diverse combination of signs and symptoms, including dis-
tortions in perception, cognitive impairments, motor abnormalities, avolition and apathy,
communication difficulties, and restricted affective expression, all of which are classified
as being either positive, negative, cognitive, disorganized, mood or motor symptoms [43].
Positive symptoms include impaired reality testing with the presence of delusions, halluci-
nations, and reality distortions. Reality distortions indicate the formal onset of schizophre-
nia [43]. The positive symptoms of schizophrenia are likely a result of dopaminergic
mesolimbic hyperactivity [44]. Negative symptoms involve the blunting of affect, which
includes loss of motivation, poverty of speech, inability to experience pleasure, and lack of
interest [45–47]. Negative symptoms can be further divided into primary and secondary
negative symptoms [47,48]. Primary “deficit syndrome” negative symptoms are intrinsic
to schizophrenia, while secondary negative symptoms are caused by extrinsic factors such
as environmental deprivation and depression [43]. In contrast to the negative symptoms
of schizophrenia, patients can also exhibit increased emotional reactivity [43]. The patho-
physiology of the negative symptoms of schizophrenia is not well understood, and the
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symptoms are largely refractory to treatment [44,49,50]. Disorganized thought refers to
the fragmentation of the logical, progressive, and goal-oriented nature of normal thought,
which can range from mild circumstantiality to fully incoherent speech in the form of
“word salad” [51]. Disorganized thought also includes derailment, clanging, and neolo-
gisms as well as poverty of thought [43]. Formal thought disorder often co-occurs with
disorganized behavior [43]. Depression is present in the majority of schizophrenia patients,
is more severe in those with substance abuse disorder, can occur in any phase of the disease,
and significantly contributes to disease burden [52–55]. Along with positive and negative
symptoms, schizophrenia also has cognitive impairment [56,57]. Cognitive impairments in-
clude impairments of episodic memory [58–60], processing speed [61], verbal fluency [62],
attention [63,64], executive functions and working memory [65–68].
6. Current Treatment of Schizophrenia
There are many effective treatments available for schizophrenia, but patients experi-
ence repeated relapses related to nonadherence with oral medication formulations. The
use of long-acting injectable (LAI) antipsychotics for patients who are unable to maintain
a steady medication regimen is beneficial in reducing rehospitalization and treatment
failure [69]. The current therapies available for schizophrenia are based on the dopamine
hypothesis, which attributes positive symptoms to increased dopamine in the mesolimbic
pathway and negative symptoms to decreased dopamine in the mesocortical pathway [70].
The dopamine D2 receptor is the primary target for drugs to alleviate psychotic symptoms,
but it is associated with elevations in prolactin and extrapyramidal side effects. The cur-
rently used antipsychotic drugs fully or partially block the effects of dopamine at the D2
receptor [71]. Dopamine exerts its effects through G-protein coupled receptors that are
further divided into the D1 subtype (D1 and D5 receptors) and D2 subtype (D2, D3, and D4
receptors) [72,73].
6.1. First- and Second-Generation Antipsychotics
The first-generation antipsychotics block mostly D2 receptors in the brain and do
not show any selectivity for the dopamine pathways present in the CNS, which leads to
unwanted side effects associated with these antipsychotic drugs such as elevated prolactin
and extrapyramidal symptoms [70]. First-generation drugs, such as haloperidol and
chlorpromazine, have clinical efficacy in reducing the positive symptoms and decreasing
the risk of relapse; however, they have little to no benefit for negative symptoms or the
cognitive impairment associated with schizophrenia. Second-generation antipsychotics,
such as clozapine and risperidone, are less likely to cause extrapyramidal symptoms (but
both medications have other side effects that patients should be made aware of) and are
efficacious in treating both positive symptoms and negative symptoms. Neither first nor
second generation is superior at treating the cognitive deficits and achieves only moderate
improvement in cognition when dosed properly [71]. Second-generation drugs and long-
acting injectable formulations of antipsychotics have been associated with greater treatment
efficacy. Specifically, long-acting injectables are more beneficial for patients with poor oral
medication compliance. A cohort study conducted in 2017 by Tiihonen et al. determined
that clozapine and long-acting injectable drugs like paliperidone are more effective at
reducing the risk of treatment failure and rehospitalization than other antipsychotic drugs.
Long-acting injectables have a 20–30% lower risk of rehospitalization compared with oral
drugs [74].
6.2. Third-Generation Antipsychotics
While first- and second-generation antipsychotics are antagonists at the D2 receptor,
third-generation antipsychotics are either partial D2 agonists or biased ligands. Third-
generation antipsychotics such as aripiprazole, cariprazine, lumateperone, and brexpipra-
zole are the newest group of antipsychotics. Since third-generation drugs have been
introduced, patients’ risk of experiencing parkinsonian symptoms, akathisia, and dystonia
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is substantially lower than with other antipsychotic agents. In general, patients that are
only on third-generation drugs have had lower side effects.
There is still variability in patient response with any class of antipsychotic drugs. Some
patients respond better to the older group of drugs, while others benefit more from a newer
class of drugs, but this can be dependent on prescriber preference or comfort of use [70].
Even with the increasing number of antipsychotic drugs available to treat schizophrenia,
management of the disease is far from optimal. Antipsychotic drugs have limitations that
include patients lacking response to drug treatment, not controlling negative symptoms
or cognitive defects, a wide range of debilitating side effects, and potential decreased
survival due to pro-arrhythmic effects. Clozapine is the drug of choice for patients who
are classified as “treatment-resistant” but has the potential to cause fatal agranulocytosis,
as well as constipation (leading to bowel obstruction), severe cardiovascular issues and
seizures. [70]. With the development of newer antipsychotics, the focus of treatment for
schizophrenia has shifted from relieving the psychotic/positive symptoms to alleviating
the negative symptoms and cognitive decline that affects the patient’s ability to recover
and integrate back into society [75].
7. Aripiprazole Lauroxil Drug Information
7.1. Dosing Information
Aripiprazole lauroxil is an FDA-approved atypical antipsychotic indicated for the
treatment of schizophrenia. Aripiprazole lauroxil can only be administered by intramuscu-
lar (IM) injection (deltoid 441 mg only or gluteal region 441 mg, 662 mg, 882 mg, 1064 mg)
from a licensed healthcare professional. This method nullifies the need for daily oral admin-
istration and will help improve adherence to treatment in patients who are nonadherent
with taking daily medications [76]. If a patient has never taken aripiprazole, oral tolerability
must be established before aripiprazole lauroxil can be administered [77]. The half-life of
oral aripiprazole is approximately 75 h, and it may take 2 weeks for some patients to reach
tolerability status [78]. Oral dosage reflects how much injection dosage is given. If the
patient were taking 10 mg per day, then they would receive a 441 mg injection every month.
If the patient were taking 15 mg per day, then they would receive 662 mg every month,
882 mg every 6 weeks or 1064 mg every 2 months. If the patient were receiving 20 mg or
higher, then they would receive a 882 mg injection every month. Oral aripiprazole should
be administered for 21 consecutive days after the first aripiprazole lauroxil injection. The
patient should be counseled on adverse reactions and side effects of the medication and
counseled to go to the emergency room. Aripiprazole lauroxil can be given as a monthly
dose of 441 mg, 662 mg, or 882 mg based on the needs of the patient. These doses are
equal to 300 mg, 450 mg, and 600 mg of aripiprazole, respectively. All doses should be
administered in the gluteal muscle except for the 441 mg dose, which can be given in the
deltoid muscle dependent on patient preference [77,79].
7.2. Contraindications and Adverse Effects
Aripiprazole lauroxil is contraindicated in patients with a known hypersensitivity
reaction to aripiprazole and is not approved for the treatment of elderly patients with
dementia-related psychosis (boxed warning). Aripiprazole lauroxil is also associated
with other adverse effects, including cerebrovascular accidents, neuroleptic malignant
syndrome, tardive dyskinesia, hyperglycemia, dyslipidemia, orthostatic hypotension,
leukopenia/neutropenia, seizures, cognitive and/or motor impairment, hyperthermia, and
dysphagia [77]. Patients with a history of leukopenia or neutropenia should be monitored
for the first few months of therapy and receive regular complete blood counts to ensure a
normal white blood cell level. There is not sufficient data to determine the risks of birth
defects or miscarriage in pregnant women using aripiprazole lauroxil, but withdrawal
symptoms and extrapyramidal side effects have been observed in infants exposed to
antipsychotics during the third trimester [80].
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8. Mechanism of Action
Aripiprazole lauroxil is a prodrug of aripiprazole and is administered as an intra-
muscular injection. Once administered, aripiprazole lauroxil is first converted to N-
hydroxymethyl aripiprazole by enzyme-mediated hydrolysis and is hydrolyzed again
to aripiprazole [81,82]. Aripiprazole was originally reported to be a partial agonist at D2
and 5HT1A receptors, with a combination of antagonistic activity at 5HT2A receptors [77,82].
At present, it has been demonstrated that aripiprazole can act as an antagonist, partial ago-
nist, or full agonist at D2 receptors [82]. Antagonistic activity at alpha1 receptors explains
some of the adverse reactions that have been reported, such as orthostatic hypotension [83].
Contrary to other second-generation antipsychotics, aripiprazole displays a higher affinity
for the dopamine receptor than the serotonin receptor. When the extracellular concen-
tration of dopamine is high, such as in the mesolimbic circuit, aripiprazole can compete
with dopamine as a partial antagonist. If the extracellular dopamine concentration is low,
namely in dopamine circuits involved in cognition and working memory, aripiprazole
can bind and partially activate other dopamine receptors. This unique mechanism of
action gives aripiprazole the name “dopamine stabilizer” as it should ideally maintain
dopamine levels in the tuberoinfundibular and nigrostriatal pathways to avoid hyperpro-
lactinemia and extrapyramidal side effects [70,75]. Aripiprazole is also a partial agonist
for D2 receptor-mediated recruitment of the β-arrestin-2 signaling pathway. This pathway
appears to be critical in minimizing extrapyramidal side effects while maintaining antipsy-
chotic efficacy [82]. Targeting the β-arrestin signaling pathways is promising in the design
of future antipsychotic drugs [70].
9. Pharmacokinetics and Pharmacodynamics
9.1. Absorption and Distribution
After injection of aripiprazole lauroxil, aripiprazole is released into the systemic circu-
lation after 5–6 days, and maximum concentration is reached approximately 41 days after
administration. To bridge the gap created by slow absorption into the systemic circulation,
patients should take oral aripiprazole for 21 days following the first injection [69]. An
alternative regimen consisting of a nano-crystalline milled version of aripiprazole lauroxil
and a 30 mg single dose of oral aripiprazole achieved the desired therapeutic dose in the
same time frame as a 441 or 882 mg injection plus the 21-day oral initiation regimen [79].
Following absorption, aripiprazole displays broad extravascular distribution and has a
volume of distribution of 268 L [83].
9.2. Metabolism
Once injected, aripiprazole lauroxil dissolves slowly and is cleaved by esterases into
N-hydroxymethyl aripiprazole and lauric acid, which is a fatty acid found in human
breast and cow’s milk. Through water-mediated hydrolysis, N-hydroxymethyl aripipra-
zole becomes aripiprazole and formaldehyde. The amount of formaldehyde formed by
the metabolism of aripiprazole lauroxil is a minute amount compared with the amount
produced by basic metabolism and a regular diet [69]. Aripiprazole lauroxil undergoes
metabolism in the liver by CYP3A4 and CYP2D6 to dehydro-aripiprazole [69,83]. Pharma-
cokinetic differences may be present in individuals who are poor metabolizers of CYP2D6,
and healthcare providers may need to adjust the dose based on patient response to treat-
ment [80].
9.3. Elimination
The mean elimination half-life of aripiprazole lauroxil after administration of the final
dose of 441 mg, 882 mg, and 1064 mg ranges from 53.9 to 57.2 days. Similar to the other
long-acting injectables available, aripiprazole lauroxil has an extended pharmacokinetic
profile due to an elimination rate that is faster than the absorption rate [84]. Thus, the
calculated half-life for the injection of aripiprazole lauroxil is greater than the half-life of
oral aripiprazole, which has a mean of 75 h [77]. After aripiprazole lauroxil is converted
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into its active metabolite, there is no measurable amount of prodrug present, making it
unlikely that the rate of conversion or distribution of aripiprazole lauroxil is the cause of
the slow elimination rate [84].
10. Clinical Studies: Safety and Efficacy
10.1. Phase I Studies
A randomized, open-label, single-dose study evaluated the bioavailability and safety
of AL in adult patients with schizophrenia. Forty-six patients were randomized into two
groups; 441-mg IM injection administered at the deltoid site or gluteal site. Although del-
toid administration resulted in higher values for both areas under the plasma concentration-
time curve from time zero to the last quantifiable plasma concentration (AUClast) and
maximum plasma concentration (Cmax) of aripiprazole and dehydro-aripiprazole, the
range of exposures overlapped for the two sites. Moreover, 38 of the 46 patients experi-
enced at least one TEAE, which were all mild or moderately intense and did not lead to
any discontinuations. The most common AE was injection-site pain, which occurred at a
higher frequency with deltoid administration (63.6%) than gluteal administration (better
absorption) (27.3%) [85].
A 44-week, open-label study evaluated the pharmacokinetics and safety of 1064-mg AL
in patients with schizophrenia by randomizing 105 patients to one of three groups; 1064-mg
dosed every 8 weeks, 882-mg dosed every 6 weeks, and 441-mg dosed every 4 weeks for
a total of 4, 5 and 7 injections. Overall, 1064-mg AL provided similar mean aripiprazole
concentrations to 882-mg AL, with both resulting in higher aripiprazole exposure than
442-mg AL. Injection-site pain was the most frequent AE in all three regimens, with the
overall incidence of injection-site reactions of 11.5%. Although most AEs were mild or
moderate, severe AEs (SAEs) occurred in all 3 groups but, with the exception of one case of
increased psychosis, were considered unrelated to AL. The incidence of discontinuation
due to TEAEs was 2.9%, 11.8% and 5.7% in the 1064-mg, 882-mg and 441-mg groups,
respectively. The incidence of AEs associated extrapyramidal symptoms (EPS) was the
highest in the 882-mg group [86].
10.2. Phase III Studies
A 12-week, randomized, double-blind, placebo-controlled study (RDBPC) demon-
strated the safety and efficacy of two doses of Aripiprazole Lauroxil (AL) in treating
patients with schizophrenia experiencing an acute relapse. Patients were randomized to
AL 441-mg, AL 882-mg or placebo, with a dosing regimen of every 4 weeks, administered
in the gluteal muscle. Outcomes studied were an improvement from baseline to day 85
in Positive and Negative Syndrome Scale (PANSS) total score and the Clinical Global
Impressions-Improvement scale (CGI-I) score at day 85 for AL groups compared with
placebo. The placebo-adjusted least-squares mean differences of PANSS total score for AL
441-mg and AL 882-mg were −10.9 (1.8) (p < 0.001) and −11.9 (1.8) (p < 0.001). The CGI-I
scores for both AL groups were also significantly better than the placebo (Wilcoxon rank
sum test: p < 0.001). The incidence of severe TEAEs was similar in all three groups, with
insomnia, akathisia, headache, and anxiety common TEAEs. Akathisia was observed to
have an incidence in the AL groups twice that of the placebo group, the only TEAE to
reach this. The overall incidence of injection-site reactions was low, and pain was the most
common injection-site reaction. The rate of discontinuation due to AEs was 6.8%, 2.9%,
and 17.9% for the 441-mg, 882-mg, and placebo groups, respectively [87].
Nasrallah et al. carried out a 52-week, open-label extension study of the 12-week
RDBPC [87] to assess changes in endocrine and metabolic parameters due to AL monother-
apy in outpatients with schizophrenia. For the whole population, there was a decrease in
serum prolactin levels, slight decreases in levels of total cholesterol and triglycerides, and
slight increases in fasting blood glucose, HbA1c, and body weight. No clinically meaning-
ful difference was found for these parameters between the two treatment arms (AL 441-mg
and 882-mg). The incidence of TEAEs was similar in both groups, with insomnia, increased
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weight and anxiety TEAEs. The rate of discontinuation due to AEs as well as the incidence
of SAEs were both higher in the 882-mg group [88].
10.3. Phase IV Studies
A prospective, 6-month, open-label study evaluated clinical outcomes and the safety
of switching to AL from paliperidone palmitate (PP) and risperidone long-acting injection
(RLAI) in 51 patients with schizophrenia who did not tolerate the latter or did not see
improvement in symptoms. Both Clinical Global Impressions–Severity (CGI-S) and Brief
Psychiatric Rating Scale (BPRS) scores showed statistically significant improvements at the
end of treatment period and after 6 months, respectively. Moreover, the overall retention
rate was 68.6%, and the incidence of discontinuation due to medication-related reasons
was <10%. The incidence of any AE was 41.2%, any SAE was 9.8%, and of drug-related AEs
was 17.6%. Common AEs included psychotic disorder (7.8%), anxiety (5.9%) and suicidal
ideation (5.9%) [89].
10.4. Other Studies
A series of post-hoc analyses of the phase 3, 12-week RDBPC [87] were performed
and are described below.
Potkin et al. carried out a subgroup analysis to evaluate the efficacy and safety
of AL treatment for patients who had severe psychotic symptoms (defined as having a
PANSS total score greater than the median score of 92). A mixed model for repeated
measures (MMRM) showed statistically significant decreases in placebo-adjusted mean
change in PANSS total score and PANSS Positive, Negative, and General Psychopathology
scores for both AL 441 mg and AL 882 mg. The overall responder rates for both AL
doses were also significantly higher compared with placebo: 49% (p < 0.001) and 61%
(p < 0.001), respectively. Finally, effect sizes for this subgroup of patients were higher
for both doses than for the group of patients with less severe symptoms (defined as
PANSS ≤ 92). Moreover, AL-882 mg resulted in a higher responder rate and also produced
a higher effect size in the more severely ill patient subgroup than the AL 441-mg. Akathisia,
headache, insomnia, and anxiety were among common AEs in the patient subgroup
analyzed [90].
Targum et al. analyzed the effect of age and gender on the treatment response of AL
versus placebo. For the analysis, patients were stratified into the following age groups:
<30, 30–39, 40–49, and 50–69 years. ANCOVA analysis showed no significant interaction
effects between age and treatment for both AL 441 mg versus placebo and AL 882 mg
versus placebo; (F = 0.27; p = 0.60) and (F = 0.92; p = 0.34), respectively. Odds ratios (ORs)
for treatment response rates, (response defined as ≥30% total PANSS score improvement
from baseline) on day 85 also showed higher association for either AL dose versus placebo
for all age groups. No interaction effect between gender and treatment was observed, with
outcomes for both men and women being better in both AL groups than placebo [91].
Correll et al. assessed social and functional outcomes using 6- and 4-item Positive
and Negative Syndrome Scale (PANSS) Prosocial subscales and Personal and Social Perfor-
mance (PSP) total score. Statistically significant improvements were observed in both 6-
and 4-item PANSS Prosocial Scores for both doses of AL versus placebo, with the treatment
effect sizes with AL 441 mg versus placebo being Cohen’s d = 0.52 and AL 882 mg versus
placebo being Cohen’s d = 0.49. PSP total score results also showed a similar trend, with
a statistically significant increase for both doses versus placebo, with treatment effect
sizes of Cohen’s d = 0.51 and 0.59 for AL 441-mg or AL 882-mg compared with placebo,
respectively [92].
Citrome et al. analyzed the effectiveness of AL using the number needed to harm
(NNH) and the number needed to treat (NNT). Pooled AL results (using both AL 441-mg
and 882-mg results) produced NNT values of 4, 6, 10 and 26 when the response thresholds
were ≥20%, ≥30%, ≥40%, and ≥50% decrease in PANSS total score from baseline to day 85,
respectively. A Cohen’s d of 0.61 (95% CI: 0.44–0.79) for the PANSS total score change and
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an NNH of −8 (95% CI: −6 to −15) for discontinuation due to AEs were both calculated
for pooled doses of AL versus placebo. Moreover, some AEs produced a statistically
significant estimate of double-digit NNH values for pooled AL doses versus placebo,
including akathisia, toothache, increased blood creatine phosphokinase, and increased
weight [93].
Nasrallah et al. analyzed the effect of AL on metabolic and endocrine parameters
such as body weight, glycemic control, and lipid and prolactin levels. At day 85, in both
AL groups relative to placebo, mean body weight increased slightly while prolactin levels
decreased in both men and women. Changes in lipid parameters (total cholesterol, LDL
cholesterol, and triglycerides), plasma glucose, and HbA1c were insignificant. The overall
incidence of AEs related to metabolic effects was low and was 2.4%, 1.4%, and 2.4% in AL
441 mg, AL 882 mg, and placebo groups, respectively [94].
Citrome et al. also analyzed the effect of AL on agitation and hostility levels of
patients with schizophrenia using three outcomes: PSP disturbing and aggressive behavior
domain, PANSS Hostility item (P7) score in the subpopulation with a PANSS Hostility
item P7 score of more than 1 at baseline, and the PANSS excited component (PANSS-EC)
score. Significant improvements occurred for all three outcomes: (p < 0.05) for reduction
in PANSS Hostility item P7 score for the subpopulation treated with 882-mg, p < 0.001
for mean change in PANSS-EC scores for both groups versus placebo, and p = 0.007 and
p < 0.001 for reduction of incidence of PSP disturbing and aggressive behavior domain for
AL 441 mg vs. placebo and AL 882 mg vs. placebo, respectively. Additionally, greater
benefits with AL 882-mg were indicated because it showed a significant reduction in
the mean PANSS Hostility item P7 score in the subpopulation, even after controlling for
positive symptoms and somnolence or akathisia, thus producing a specific anti-hostility
effect, and also showed greater improvement than AL 441mg group for PANSS-EC [95].
McEvoy et al. carried out an analysis of the 52-week extension study [88] to evaluate
the durability of long-term AL treatment in a subgroup population (patients who had
completed both the initial 12-week study and the subsequent 52-week study and were
randomized to either the AL 441-mg group or 882-mg group in the extension study). For
both AL groups, a statistically significant decrease occurred for both PANSS total score
and CGI-S scores from week 12 to week 64. By week 64, remission rates were 73.8% and
68.1% in the 441 mg and 882 mg groups, respectively, with the median remission time from
the beginning of the 12 weeks being 16.1 and 16.4 weeks, respectively. Rates of treatment
discontinuation were low for the 441 mg (27.25) and 882 mg (34%) groups in the extension
study, with withdrawal due to adverse events being 2.5% and 5%, respectively [96].
Moreover, a targeted systematic review of 31 RCTs (7 primary studies and 24 post-
hoc analyses) compared LAIs to placebo, oral antipsychotics (OAPs) and other LAIs.
AL was among the LAIs included. Results showed that LAIs were wholly superior to
placebo and partly superior to OAPs regarding prevention of relapse and hospitalization,
with no observed differences in comparison to other LAIs. LAIs were comparable to
OAPs in other domains such as all-cause discontinuation, functioning, quality of life, and
tolerability and were associated with higher patient satisfaction and service engagement.
Moreover, although results from recent meta-analyses were inconclusive, they did not
show an advantage for OAPs over LAIs [97]. Table 2 summarizes the studies discussed in
this section.
10.5. Comparison Study
A network meta-analysis (NMA) carried out an indirect comparison between AL
and paliperidone palmitate (PP) using data from four Phase III clinical trials. Results
demonstrated that all four effective-treatment arms (AL 441 mg and 882 mg; and PP 156 mg
and 234 mg) showed effectiveness by reductions in PANSS total score versus placebo. The
extent of these reductions was similar, with the range of mean differences spanning from
−8.12 to −12.01, with overlapping 95% credible intervals. These results, in addition to a
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similar incidence of TEAEs for both AL and PP, supported the finding that AL and PP were
equally efficacious [98].
A study evaluated the differences in the steady-state aripiprazole plasma concen-
trations of two long-acting injectable (LAI) formulations of aripiprazole: aripiprazole
once-monthly 400 mg (AOM 400) and AL. The outcomes measured were the median min-
imum plasma concentration at steady state (Cmin,ss), calculated based on observations
from previous clinical trials, and the average plasma concentration at steady state (Cavg,ss),
based on simulations. Cavg,ss values for AOM 400 and AL 882 mg administered every
4 weeks were comparable, while AL 441 mg resulted in considerably lower Cavg,ss values.
Cmin,ss values for the intragluteal injection of AOM 400 and the intragluteal injection
of AL 882 mg every 4 weeks were also found to be similar (200 ng/mL and 175 ng/mL,
respectively) [99]. Table 1 summarizes the comparative studies discussed here.
Table 1. Comparative studies.
Author (Year) Groups Studied and Intervention Results and Findings Conclusions
Cameron C. et al.
(2017) [98]
A NMA, with searches from MED- LINE,
Embase, Cochrane CENTRAL, PsycINFO,
ClinicalTrials.gov, International Clinical
Trials Registry Platform, and gray
literature which identified four Phase III
clinical trials (1 of AL and 3 of PP), for
indirect comparison of AL and PP.
Active-treatment groups were AL (441 mg
and 882 mg monthly) and PP (156 mg and
234 mg monthly).
All four groups versus placebo
resulted in substantial reduction
in acute symptoms, as measured
by the positive and negative
syndrome scale; the range of
mean difference was −8.12 to
−12.01, with overlapping 95%
credible intervals. No differences
in efficacy, safety or tolerability
were found between
active-treatment groups.
AL and PP are equally
efficacious in treating adults
with acute exacerbation of
schizophrenia.
Salzman P. et al.
(2017) [99]
Aripiprazole steady-state plasma
concentrations for two different LAI
formulations, (aripiprazole once-monthly
400 mg [AOM 400] and AL), were
compared. Cavg,ss for AOM 400 were
obtained from a population Pk model,
while those for AL were obtained from the
Center for Drug Evaluation and Research
(CDER). Cmin,ss for both LAIs were
obtained from previously published
clinical trials.
Cavg,ss values for AOM 400 and
AL 882 mg given every 4 weeks
were comparable, while AL 441
mg resulted in considerably lower
Cavg,ss values. Cmin,ss values for
the intragluteal injection of AOM
400 and the intragluteal injection
of AL 882 mg every 4 weeks were
also similar (200 ng/mL and 175
ng/mL, respectively).
Both AOM 400 mg and AL




Table 2. Clinical efficacy and safety.
Author (Year) Groups Studied andIntervention Results and Findings Conclusions
Turncliff R. et al.
(2014) [85]
A phase 1, randomized,
open-label, single-dose study. 46
patients were randomized to two
groups; 441 mg IM injection
administered at deltoid site or 441
mg IM injection at gluteal site.
Maximum plasma concentration
(Cmax) and area under the plasma
concentration time curve from
time zero to infinity (AUC0–inf) of
aripiprazole and its metabolite
dehydro-aripiprazole were
measured. AEs were measured as
tolerability outcomes
Deltoid administration resulted in
higher Cmax aripiprazole
concentration, while AUC0–inf
was similar for both sites.
Dehydro-aripiprazole exposure
was 33% and 36% of aripiprazole
exposure for deltoid and gluteal
administration, respectively. The
most common AE was injection
site pain, with a higher incidence
in the deltoid group.
Deltoid and gluteal injection sites
provided similar levels of
exposure and were both
well-tolerated in patients with
chronic stable schizophrenia.
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Meltzer H. et al.
(2015) [87]
A phase 3, randomized,
double-blind, placebo-controlled
trial. 623 patients (ages 18–70)
experiencing an acute
exacerbation of schizophrenia
were randomized 2:2:1:1 to AL 441
mg, AL 882 mg, placebo low
volume, and placebo high volume,
respectively. Injections were
administered in the gluteal
muscle on days 1, 29 and 57. The
primary efficacy endpoint was
change from baseline to day 85 in
PANSS total score, and the
secondary efficacy endpoint was
CGI-I score at day 85.
Placebo-adjusted least squares
mean differences of PANSS total
score were significantly lower for
both AL 441 mg and AL 882 mg; p
< 0.001 for both. CGI-I scores for
both AL groups were also
significantly better than placebo
(Wilcoxon rank sum test: p <
0.001).
Both doses of AL were highly
efficacious in treating an acute
exacerbation of schizophrenia,
with a safety and tolerability
profile similar to oral aripiprazole,
therefore representing a new
treatment option.
Nasrallah H. et al.
(2016) [94]
Patients with schizophrenia were
randomly assigned to AL 441 mg,
AL 882 mg, or placebo
intramuscularly. Body weight,
body mass index, fasting blood
glucose and serum lipids,
glycosylated hemoglobin
(HbA1c), and prolactin were the
parameters evaluated for 12
weeks. Treatment-emergent
adverse events (AEs) were used
for safety evaluations.
For both AL groups compared
with placebo, mean body weight
increased slightly and prolactin
levels decreased, while changes in
lipid parameters (total cholesterol,
LDL cholesterol and triglycerides),
plasma glucose, and HbA1c were
insignificant. The incidence of
AEs related to metabolic
parameters was low.
Both AL 441 mg and AL 882 mg
showed a small weight gain
compared with placebo but
otherwise reflected a low-risk
metabolic profile.
Citrome L. et al.
(2016) [95]
Patients with schizophrenia were
randomly assigned to AL 441 mg,
AL 882 mg, or placebo
intramuscularly. Study endpoints
were PANSS Hostility item (P7)
score in the subpopulation of
patients with a PANSS Hostility
item P7 score of more than 1 at
baseline, PSP disturbing and
aggressive behavior domain and
PANSS excited component
(PANSS-EC) score.
AL groups compared with
placebo resulted in significant
lowering in proportion with
PANSS Hostility item P7 more
than 1 at endpoint (p < 0.05), as
well as significant improvement (p
< 0.05) in PANSS excited
component score. The proportion
of patients with aggressive
behavior on the Personal and
Social Performance scale was also
significantly lower for both 441
mg and 882 mg compared with
placebo (p = 0.006 and p < 0.001,
respectively).
AL treatment displayed efficacy
in reducing agitation and hostility
in patients with schizophrenia.
Nasrallah H. et al.
(2017) [88]
Phase 3, international, 52-week,
open-label extension study with
478 patients. 368 received AL 882
mg and 110 received AL 441 mg
as their fixed-dose regimen. Of
the 478, 236 entered from a phase
3 study and 242 entered as
outpatients with no prior AL
exposure and a Clinical Global
Impression–Severity score of ≤3
[mild] at screening. Metabolic
parameters of weight, fasting
blood sugar, lipids and serum
prolactin were assessed for
changes
The mean changes from baseline
in the overall population were
+1.1 mg/dL for glucose, +0.07 for
glycated hemoglobin (HbAlc),
−3.3 mg/dL for total cholesterol,
and −5.3 mg/dL for triglycerides,
while prolactin change from
baseline was −8.7 ng/mL (14.7)
for men and −14.9 (43.4) ng/mL
for women. The retention rates at
6 months and 1 year were 86%
and 68%, respectively.
Long-term AL treatment lead to
slight lowering of serum with
insubstantial changes in other
assessed parameters.
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Potkin S. et al.
(2017) [90]
Patients with schizophrenia were
randomly assigned to AL 441 mg,
AL 882 mg, or placebo
intramuscularly. Post-hoc analysis
of the patient subgroup with
severe psychotic symptoms
(PANSS total score greater than
the median score of 92). Primary
outcome measured was mean
change from baseline to day 85 in
PANSS Total score. Categorical
responder rate (defined as ≥30%
improvement in PANSS Total
score or a final CGI-I score of ≤2
[very much or much improved])
was also evaluated.




PANSS Total score, with
placebo-adjusted differences of
−14.7 (p < 0.0001) and −16.6 (p <
0.0001), respectively, as well as
significant findings with
responder rates (p < 0.001) for
both groups vs. placebo.
Moreover, AL-882 mg resulted in
a higher responder rate.
Both doses of AL demonstrated
robust efficacy in treating patients
with severe psychotic symptoms.
The 882 mg dose displayed a
numerically greater improvement
in symptoms and proportion of
responders.
Targum S. et al.
(2017) [91]
Patients with schizophrenia were
randomly assigned AL 441 mg,
AL 882 mg, or placebo
intramuscularly. Post-hoc gender
and age analysis of AL treatment
response, with age groups <30,
30–39, 40–49, and 50–69 years old.
The primary outcome measured
was change in total PANSS score
from baseline to day 85.
Categorical treatment response
(defined as ≥30% total PANSS
score improvement from baseline)
was also measured.
ANCOVA analysis of change in
PANSS score showed no
significant interaction effects
between age and treatment for
both AL 441 mg versus placebo
and AL 882 mg versus placebo; (F
= 0.27; p = 0.60) and (F = 0.92; p =
0.34), respectively. The odds ratios
(ORs) for treatment response rates
showed higher association for
either AL dose versus placebo for
all age groups.
No interaction effect between
gender and treatment was
observed, with outcomes for both
men and women being better in
AL groups than placebo.
AL 441 mg and AL 882 mg led to
significant improvement in mean
total PANSS score and categorical
treatment response compared
with placebo, regardless of patient
age and gender.
McEvoy J. et al.
(2017) [96]
Post-hoc analysis of long-term
outcomes in patients who had
completed both a phase 3 and
extension study. Outcomes
measured were rates of retention
and remission, as well as
treatment response trajectories, as
measured by PANSS total and
CGI-S item scores in AL 441 mg
and AL 882 mg groups.
A statistically significant decrease
occurred for PANSS total score (p
< 0.0001 for both groups) and
CGI-S scores ((p < 0.0001 for both
groups). By week 64, remission
rates were 73.8% and 68.1% in the
441 mg and 882 mg groups,
respectively, with the median
remission time from the
beginning of the 12 weeks being
16.1 and 16.4 weeks, respectively.
Retention rates were 72.8% and
66.0% for the 441 mg and 882 mg
groups, respectively.
Both Al 441 mg and AL 882 mg
exhibited continued therapeutic
benefit in the long-term, as
evidenced by high retention rates
and significant improvements in
clinical symptoms.
Miller B. et al.
(2019) [89]
A phase 4, 6-month, prospective,
open-label study in which 51
patients switched from either PP
or RLAI to AL. Outcomes
measured were CGI-S scores,
BPRS scores, all-cause and
medication-related
discontinuation and adverse
events. AEs were also assessed.
CGI-S and BPRS scores showed
significant improvement, and the
retention rate with all-cause and
medication-related
discontinuation rates at the end of
6 months was 30% and 9%,
respectively. The retention rate at
the end of 6 months was 68.6%,
while the incidence of AEs was
41.2%, with the most frequent
psychotic disorder, anxiety and
schizophrenia.
Patients being treated with PP or
RLAI who experience continued
symptoms or tolerability issues
can switch to AL, as the latter is
well-tolerated.
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Correll C. et al.
(2019) [92]
Patients with schizophrenia were
randomly assigned to AL 441 mg,
AL 882 mg, or placebo
intramuscularly. Post-hoc social
and functional outcomes analysis
of 596 of the total 623 patients.
Outcomes measured were 6-item
PANSS Prosocial subscale, 4-item
PANSS Prosocial subscale and
Personal and Social Performance
(PSP) total score.
Both 6- and 4-item PANSS
Prosocial Scores showed
significant improvement for both
doses of AL versus placebo, with
the treatment effect sizes for
PANSS Prosocial scores with AL
441 mg versus placebo being
Cohen’s d=0.52 and AL 882 mg
versus placebo being Cohen’s
d=0.49. There was a significant
increase in PSP total score for both
doses versus placebo, with
treatment effect sizes of Cohen’s d
= 0.51 and 0.59 for AL 441-mg or
AL 882-mg compared with
placebo, respectively.
Treatment with AL 441 mg and




Citrome L. et al.
(2019) [93]
Patients with schizophrenia were
randomly assigned to AL 441 mg,
AL 882 mg, or placebo
intramuscularly. Post-hoc analysis
with categorical efficacy and
tolerability. Outcomes measured
were number needed to treat
(NNT) for therapeutic outcomes,
number needed to harm (NNH)
for adverse outcomes, and
likelihood to be helped or harmed
(LHH).
For pooled doses of AL, an NNT
of 6 (95% CI: 5–11) was calculated
when the response threshold was
≥30% improvement from baseline
PANSS total score.
For discontinuation due to AEs, a
NNH estimate of −8 (95% CI: −6
to −15) for the pooled doses of
AL vs placebo was calculated,
while for Akathisia, the NNH was
14 (95% CI: 9–33). LHH value,
using the NNT for response
(≥30% reduction from baseline in
PANSS total score) and the NNH
for akathisia, was 2.3.
Aripiprazole lauroxil is efficacious
and well-tolerated in the
treatment of an acute exacerbation
of schizophrenia, as evidenced by
NNT and NNH values.
Peters L. et al.
(2019) [97]
A systematic review of 31 RCTs (7
primary studies and 24 post hoc
analyses) to evaluate comparisons
of LAIs to placebo, OAPs or
another LAI and 5 meta-analyses
of RCTs comparing LAI to OAPs,
all published 2016–2019. AL was
among the LAIs analyzed.
LAIs were vastly superior to
placebo and partly superior to
OAPs for prevention of relapse
and hospitalization and were
comparable to OAPs for all-cause
discontinuation, functioning,
quality of life, and tolerability, as
well as being associated with
higher patient satisfaction and
service engagement. Results from
recent meta-analyses did not show
an advantage for OAPs over LAIs.
Results from RCTs show that LAIs
outperform placebo but are better
than OAPs in only some aspects.
Meta-analyses results do not
reveal an advantage for OAP vs.
placebo.
Weiden P. et al.
(2020) [86]
A phase I, open-label, multicenter
study, with 105 patients
randomized to one of three AL
dose regimens of 1064-mg
injections every 8 weeks, 882-mg
injections every 6 weeks, or
441-mg injections every 4 weeks,




Both 1064-mg and 882-mg
regimens provided comparable
aripiprazole exposure, higher
than that of 441-mg. Most AEs
were mild or moderate, with
injection-site pain being the most
frequent AE in all three regimens.
Discontinuation due to TEAEs
was 2.9%, 11.8% and 5.7% in the
1064-mg, 882-mg and 441-mg
groups, respectively.
All three dosing regimens provide
continuous exposure to AL,
including 1064-mg administered
every 2 months, and all produced




Schizophrenia consists of positive symptoms, negative symptoms, and cognitive
dysfunction. Several theories regarding pathogenesis have been proposed, including the
neurodevelopmental theory and dopaminergic imbalance. There are several risk factors
that contribute to the development of schizophrenia, including genetic factors, history of
cannabis use, and childhood trauma. The pharmacological treatment of schizophrenia is
largely based on mitigating dopaminergic imbalance.
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First-generation antipsychotics work by non-selectively blocking D2 receptors in the
CNS. While effective at mitigating positive symptoms, FGAs lead to unwanted extrapyra-
midal symptoms and elevated prolactin levels due to non-selectivity. FGAs have not
been shown to reduce negative symptoms or improve cognitive impairment. Second
generation antipsychotics also work by blocking dopaminergic receptors. SGAs have been
shown to produce less extrapyramidal symptoms and can treat both positive and negative
symptoms; however, SGAs show no improvement in cognitive dysfunction. Third genera-
tion antipsychotics, including aripiprazole, can be characterized as D2 partial agonists or
D2-biased ligands.
Aripiprazole can act as an antagonist in areas with high dopamine levels and an
agonist in areas with low dopamine levels, thus giving it the name “dopamine stabilizer.”
The use of aripiprazole has also been shown to minimize extrapyramidal symptoms when
compared with first- and second-generation antipsychotics. Aripiprazole lauroxil is a pro-
drug of aripiprazole and is given as an IM injection, which helps improve treatment rates
in patients who are not compliant in taking once-daily oral medication. AL is metabolized
by CYP3A4 and CYP2D6 in the liver. The use of AL is contraindicated in patients with
known aripiprazole hypersensitivity and in dementia-related psychosis. Side effects are
known to include weight gain, akathisia, neuroleptic malignant syndrome, tardive dyski-
nesia, orthostatic hypotension due to alpha1 blockade, leukopenia, and neutropenia. The
use of AL has shown significant statistical and clinical efficacy in treating the symptoms
of schizophrenia.
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